MRK-409 is a GABA-A receptor agonist A31972.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | MRK-409 may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of MRK-409. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of MRK-409. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of MRK-409. |
| Hydrocodone | MRK-409 may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of MRK-409. |
| Magnesium sulfate | The therapeutic efficacy of MRK-409 can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | MRK-409 may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | MRK-409 may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of MRK-409. |
| Mirtazapine | MRK-409 may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of MRK-409. |
| Orphenadrine | MRK-409 may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | MRK-409 may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of MRK-409. |
| Pramipexole | MRK-409 may increase the sedative activities of Pramipexole. |
| Ropinirole | MRK-409 may increase the sedative activities of Ropinirole. |
| Rotigotine | MRK-409 may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with MRK-409. |
| Sodium oxybate | MRK-409 may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | MRK-409 may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of MRK-409. |
| Thalidomide | MRK-409 may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | MRK-409 may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Yohimbine | The therapeutic efficacy of MRK-409 can be increased when used in combination with Yohimbine. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with MRK-409. |
| Ethanol | MRK-409 may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | MRK-409 may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of MRK-409. |
| Fluvoxamine | The risk or severity of adverse effects can be increased when MRK-409 is combined with Fluvoxamine. |
| Citalopram | The risk or severity of adverse effects can be increased when MRK-409 is combined with Citalopram. |
| Duloxetine | The risk or severity of adverse effects can be increased when MRK-409 is combined with Duloxetine. |
| Trazodone | The risk or severity of adverse effects can be increased when MRK-409 is combined with Trazodone. |
| Paroxetine | The risk or severity of adverse effects can be increased when MRK-409 is combined with Paroxetine. |
| Sertraline | The risk or severity of adverse effects can be increased when MRK-409 is combined with Sertraline. |
| Sibutramine | The risk or severity of adverse effects can be increased when MRK-409 is combined with Sibutramine. |
| Nefazodone | The risk or severity of adverse effects can be increased when MRK-409 is combined with Nefazodone. |
| Escitalopram | The risk or severity of adverse effects can be increased when MRK-409 is combined with Escitalopram. |
| Zimelidine | The risk or severity of adverse effects can be increased when MRK-409 is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when MRK-409 is combined with Dapoxetine. |
| Milnacipran | The risk or severity of adverse effects can be increased when MRK-409 is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of adverse effects can be increased when MRK-409 is combined with Desvenlafaxine. |
| Seproxetine | The risk or severity of adverse effects can be increased when MRK-409 is combined with Seproxetine. |
| Indalpine | The risk or severity of adverse effects can be increased when MRK-409 is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when MRK-409 is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when MRK-409 is combined with Alaproclate. |
| Amitriptyline | The risk or severity of CNS depression can be increased when Amitriptyline is combined with MRK-409. |
| Cyproheptadine | The risk or severity of CNS depression can be increased when Cyproheptadine is combined with MRK-409. |
| Imipramine | The risk or severity of CNS depression can be increased when Imipramine is combined with MRK-409. |
| Nortriptyline | The risk or severity of CNS depression can be increased when Nortriptyline is combined with MRK-409. |
| Amoxapine | The risk or severity of CNS depression can be increased when Amoxapine is combined with MRK-409. |
| Propiomazine | The risk or severity of CNS depression can be increased when Propiomazine is combined with MRK-409. |
| Maprotiline | The risk or severity of CNS depression can be increased when Maprotiline is combined with MRK-409. |
| Doxepin | The risk or severity of CNS depression can be increased when Doxepin is combined with MRK-409. |
| Desipramine | The risk or severity of CNS depression can be increased when Desipramine is combined with MRK-409. |
| Pizotifen | The risk or severity of CNS depression can be increased when Pizotifen is combined with MRK-409. |
| Dosulepin | The risk or severity of CNS depression can be increased when Dosulepin is combined with MRK-409. |
| Zopiclone | The risk or severity of adverse effects can be increased when MRK-409 is combined with Zopiclone. |
| Botulinum toxin type B | The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with MRK-409. |
| Botulinum toxin type A | The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with MRK-409. |
| Tryptophan | The risk or severity of CNS depression can be increased when Tryptophan is combined with MRK-409. |
| Baclofen | Baclofen may increase the central nervous system depressant (CNS depressant) activities of MRK-409. |
| Lorazepam | The risk or severity of CNS depression can be increased when Lorazepam is combined with MRK-409. |
| Ethchlorvynol | The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with MRK-409. |
| Succinylcholine | The risk or severity of CNS depression can be increased when Succinylcholine is combined with MRK-409. |
| Reserpine | The risk or severity of CNS depression can be increased when Reserpine is combined with MRK-409. |
| Eletriptan | The risk or severity of CNS depression can be increased when Eletriptan is combined with MRK-409. |
| Enflurane | The risk or severity of CNS depression can be increased when Enflurane is combined with MRK-409. |
| Temazepam | The risk or severity of CNS depression can be increased when Temazepam is combined with MRK-409. |
| Reboxetine | The risk or severity of CNS depression can be increased when Reboxetine is combined with MRK-409. |
| Butabarbital | The risk or severity of CNS depression can be increased when Butabarbital is combined with MRK-409. |
| Butalbital | The risk or severity of CNS depression can be increased when Butalbital is combined with MRK-409. |
| Methysergide | The risk or severity of CNS depression can be increased when Methysergide is combined with MRK-409. |
| Cabergoline | The risk or severity of CNS depression can be increased when Cabergoline is combined with MRK-409. |
| Phenytoin | The risk or severity of CNS depression can be increased when Phenytoin is combined with MRK-409. |
| Topiramate | The risk or severity of CNS depression can be increased when Topiramate is combined with MRK-409. |
| Clemastine | The risk or severity of CNS depression can be increased when Clemastine is combined with MRK-409. |
| Venlafaxine | The risk or severity of CNS depression can be increased when Venlafaxine is combined with MRK-409. |
| Etomidate | The risk or severity of CNS depression can be increased when Etomidate is combined with MRK-409. |
| Morphine | The risk or severity of CNS depression can be increased when Morphine is combined with MRK-409. |
| Talbutal | The risk or severity of CNS depression can be increased when Talbutal is combined with MRK-409. |
| Pentobarbital | The risk or severity of CNS depression can be increased when Pentobarbital is combined with MRK-409. |
| Valproic acid | The risk or severity of CNS depression can be increased when Valproic acid is combined with MRK-409. |
| Zolmitriptan | The risk or severity of CNS depression can be increased when Zolmitriptan is combined with MRK-409. |
| Codeine | The risk or severity of CNS depression can be increased when Codeine is combined with MRK-409. |
| Dihydroergotamine | The risk or severity of CNS depression can be increased when Dihydroergotamine is combined with MRK-409. |
| Tolcapone | The risk or severity of CNS depression can be increased when Tolcapone is combined with MRK-409. |
| Hydromorphone | The risk or severity of CNS depression can be increased when Hydromorphone is combined with MRK-409. |
| Olanzapine | The risk or severity of CNS depression can be increased when Olanzapine is combined with MRK-409. |
| Cetirizine | The risk or severity of CNS depression can be increased when Cetirizine is combined with MRK-409. |
| Protriptyline | The risk or severity of CNS depression can be increased when Protriptyline is combined with MRK-409. |
| Trimethadione | The risk or severity of CNS depression can be increased when Trimethadione is combined with MRK-409. |
| Clobazam | The risk or severity of sedation, somnolence, and CNS depression can be increased when Clobazam is combined with MRK-409. |
| Chlorzoxazone | The risk or severity of CNS depression can be increased when Chlorzoxazone is combined with MRK-409. |
| Clozapine | The risk or severity of CNS depression can be increased when Clozapine is combined with MRK-409. |
| Meprobamate | The risk or severity of CNS depression can be increased when Meprobamate is combined with MRK-409. |
| Thiethylperazine | The risk or severity of CNS depression can be increased when Thiethylperazine is combined with MRK-409. |
| Palonosetron | The risk or severity of CNS depression can be increased when Palonosetron is combined with MRK-409. |
| Sulpiride | The risk or severity of CNS depression can be increased when Sulpiride is combined with MRK-409. |
| Alprazolam | The risk or severity of CNS depression can be increased when Alprazolam is combined with MRK-409. |